Giant skull base collision tumors in NF2-related schwannomatosis: longitudinal outcomes of planned selective resection
Journal of Neuro-Oncology · 2026-06 · 178 (2)
DOI: 10.1007/s11060-026-05641-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 08.06.2026. Verfasst von Peyton L Nisson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Skull Base Neoplasms, Neurofibromatoses, Neurilemmoma, Neurofibromatosis 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: House Clinic.
Abstract (Originalsprache)
OBJECTIVES: Giant skull base collision tumors in neurofibromatosis type 2-related schwannomatosis (NF2-SWN) pose a complex surgical challenge in young patients with lifelong tumor burden. Gross total resection is often impossible without severe neurological morbidity, and data on operative timing and durability are limited. We assessed long-term outcomes of planned, selective resection prioritizing neurological preservation. METHODS: We queried a prospective institutional database for NF2-SWN patients undergoing surgery for giant (≥ 4.0 cm) intracranial skull base collision tumors (≥ 2 neoplasms forming one mass) from January 2009 to December 2025. Surgery targeted symptomatic or high-risk components, accepting residual disease. Outcomes included time to reoperation, overall survival, and functional status. RESULTS: Thirteen patients underwent 31 skull base operations. Mean age at first surgery was 27 years (range 19-42), with mean tumor diameter 5.0 cm (range 4.0-7.7 cm). Most (69%) had prior surgery and/or radiotherapy. Gross total resection was never achieved. Over mean 9.4-year follow-up, Kaplan-Meier analysis demonstrated reoperation-free survival of 61.5% at 5 years (95% CI, 26.6-83.7%), with a median reoperation-free survival of 6.1 years. The mean interval between reoperations was 4.8 years (median, 3.9 years; IQR, 2.7-5.7; range, 0.8-14.6). Overall survival was 100% at 5 years and 88% at 10 years. At last follow-up, median Karnofsky Performance Status was 70. CONCLUSION: Planned, selective resection of giant NF2-related skull base collision tumors yielded a median reoperation-free interval of 6.1 years and maintained functional independence in a young, heavily pretreated population, supporting its feasibility as a longitudinal management strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.
- House Ear Institute, Los Angeles, CA, USA.
- Department of Pathology, University of California Los Angeles, Los Angeles, CA, USA.
- Department of Head and Neck Surgery, University of California Los Angeles, Los Angeles, CA, USA.
- Department of Neurosurgery, University of California Los Angeles, 300 Stein Plaza Suite 420, Los Angeles, CA, 90095, USA. glekovic@mednet.ucla.edu.
Förderung
- House Clinic
Zitieren
APA
Nisson, P. L., Curry, S., Zhang, T., Ishiyama, A., Slattery, W. H., Brackmann, D. E., & Lekovic, G. P. (2026). Giant skull base collision tumors in NF2-related schwannomatosis: longitudinal outcomes of planned selective resection. Journal of Neuro-Oncology, 178(2). https://doi.org/10.1007/s11060-026-05641-0
Vancouver
Nisson PL, Curry S, Zhang T, Ishiyama A, Slattery WH, Brackmann DE, et al. Giant skull base collision tumors in NF2-related schwannomatosis: longitudinal outcomes of planned selective resection. Journal of Neuro-Oncology. 2026;178(2). doi:10.1007/s11060-026-05641-0
BibTeX
@article{Nisson2026,
author = {Nisson, Peyton L and Curry, Steven and Zhang, Ting and Ishiyama, Akira and Slattery, William H and Brackmann, Derald E and Lekovic, Gregory P},
title = {Giant skull base collision tumors in NF2-related schwannomatosis: longitudinal outcomes of planned selective resection},
journal = {Journal of Neuro-Oncology},
year = {2026},
volume = {178},
number = {2},
doi = {10.1007/s11060-026-05641-0}
}
EUVIMED